Predictors of early death in a cohort of Ethiopian patients treated with HAART

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Jerene, Degu ^a,b   Endale, Aschalew ^b   Hailu, Yewubnesh ^b   Lindtjøorn, Bernt ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b Arba Minch Hospital   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD CELL COUNT; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; ETHIOPIA; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL; UNIVARIATE ANALYSIS; WEIGHT REDUCTION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; ETHIOPIA; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS;

EID: 33748900460     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-136     Document Type: Article

References (27)

1. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhate N, Toure Kane NC, Laniece I, Ndir A, Vergne L, Ndoye I, Mboup S, Sow PS, Delaporte E: Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-I-infected adults. J Acquir Immune Defic Syndr 2005, 38(1):14-17.
2. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright PF, Gulick R, Johnson WD Jr, Pape JW, Fitzgerald DW: Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005, 353(22):2325-2334.
3. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M: Mortality of HIV-I-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367(9513):817-824.
4. Stephenson J: Cheaper HIV drugs for poor nations bring a new challenge: monitoring treatment. JAMA 2002, 288(2):151-153.
5. Colebunders R, Moses KR, Laurence J, Shihab HM, Semitala F, Lutwama F, Bakeera-Kitaka S, Lynen L, Spacek L, Reynolds SJ, Quinn TC, Viner B, Mayanja-Kizza H: A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis 2006, 6(1):53-59.
6. Badri M, Wood R: Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS 2003, 17(4):541-545.
7. Lee SS, Wong KH: The use of total lymphocyte count (TLC) as an independent criterion for initiating HAART in resource-poor countries. J Infect 2005, 50(1):66-67.
8. Mahajan AP, Hogan JW, Snyder B, Kumarasamy N, Mehta K, Solomon S, Carpenter CC, Mayer KH, Flanigan TP: Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings. J Acquir Immune Defic Syndr 2004, 36(1):567-575.
9. Mekonnen Y, Dukers NH, Sanders E, Dorigo W, Wolday D, Schaap A, Geskus RB, Coutinho RA, Fontanet A: Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS 2003, 17(6):815-819.
10. Moore D, Montaner J: Total lymphocyte counts and ART in resource-limited settings. Lancet 2005, 366(9500):1831-1832.
11. van der Ryst E, Kotze M, Joubert G, Steyn M, Pieters H, van der West-huizen M, van Staden M, Venter C: Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-I-infected South African patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19(3):238-244.
12. MOH/HAPCO/DACA: Guidelines for use of antiretroviral drugs in Ethiopia. 2003.
13. Jerene D, Lindtjorn B: Disease progression among untreated HIV-infected patients in South Ethiopia: implications for patient care. MedGenMed 2005, 7(3):66.
14. Jerene D, Naess A, Lindtjorn B: Antiretroviral therapy at a district hospital in Ethiopia prevents death and tuberculosis in a cohort of HIV patients. AIDS Res Ther 2006, 3(1):10.
15. MOH: Guidelines for laboratory HIV testing in blood safety, surveillance, VCT and ARV use. 2003.
16. WHO: Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemol Rec 1990, 65:221-228.
17. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E: Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006, 20(8):1181-1189.
18. Lawn SD, Myer L, Orrell C, Bakker LG, Wood R: Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005, 19(18):2141-2148.
19. Anastos K, Shi Q, French AL, Levine A, Greenblatt RM, Williams C, DeHovitz J, Delapenha R, Hoover DR: Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-I-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004, 35(4):383-392.
20. Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB: Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. J Acquir Immune Defic Syndr 2005, 39(5):620-625.
21. Spacek LA, Griswold M, Quinn TC, Moore RD: Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS 2003, 17(9):1311-1317.
22. van der Sande MA, Schim van der Loeff MF, Aveika AA, Sabally S, Togun T, Sarge-Njie R, Alabi AS, Jaye A, Corrah T, Whittle HC: Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr 2004, 37(2):1288-1294.
23. Wanyenze R, Kamya M, Liechty CA, Ronald A, Guzman DJ, Wabwire-Mangen F, Mayanja-Kizza H, Bangsberg DR: HIV Counseling and Testing Practices at an Urban Hospital in Kampala, Uganda. AIDS Behav 2006:1-7.
24. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL: Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 31(2):230-236.
25. Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke C: Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr 2005, 40(1):70-76.
26. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL: Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 31(3):803-805.
27. Jacobson DL, Bica I, Knox TA, Wanke C, Tchetgen E, Spiegelman D, Silva M, Gorbach S, Wilson IB: Difficulty swallowing and lack of receipt of highly active antiretroviral therapy predict acute weight loss in human immunodeficiency virus disease. Clin Infect Dis 2003, 37(10):1349-1356.